Du är här

2016-03-14

Ablynx: PUBLICATION IN ACCORDANCE WITH ARTICLE 14 OF THE BELGIAN LAW OF 2 MAY 2007 REGARDING THE PUBLICATION OF MAJOR SHAREHOLDINGS (THE "TRANSPARENCY LAW")

REGULATED INFORMATION

GHENT, Belgium, 14 March 2016
-Ablynx[Euronext Brussels: ABLX; OTC: ABYLY]

today announced, in accordance with Article 14 of the Belgian Law of 2 May
2007 regarding the publication of major shareholdings in issuers whose
securities are admitted to trading on a regulated market (the "Transparency
Law"), that it received a notification of shareholdings from Aviva plc and
Aviva Investors Global Services Limited.

The above shareholders have notified Ablynx that they have dropped below the
3% threshold and now hold 901,029 Ablynx shares, which represent 1.64% of the
current 55,108,065 outstanding Ablynx shares.

The voting rights are managed and controlled by Aviva Investors Global
Services Limited, with the following chain of controlled undertakings: Aviva
plc (Parent Company), Aviva Group Holdings Limited (wholly owned subsidiary
of Aviva plc), Aviva Investors Holdings Limited (wholly owned subsidiary of
Aviva Group Holdings Limited), Aviva Investors Global Services Limited
(wholly owned subsidiary of Aviva Investors Holdings Limited).

Full versions of all transparency notifications are available on Ablynx
website, under the sectionInvestors.

About Ablynx

Ablynxis a biopharmaceutical company engaged in the development ofNanobodies®,
proprietary therapeutic proteins based on single-domain antibody fragments,
which combine the advantages of conventional antibody drugs with some of the
features of small-molecule drugs. Ablynx is dedicated to creating new
medicines which will make a real difference to society. Today, the Company
has more than40 proprietary and partnered programmesin development in various
therapeutic areas including inflammation, haematology, immuno-oncology,
oncology and respiratory disease. The Company has collaborations with
multiple pharmaceutical companies including AbbVie, Boehringer Ingelheim,
Eddingpharm, Genzyme, Merck&Co., Inc., Merck KGaA, Novartis, Novo Nordisk and
Taisho Pharmaceutical Co., Ltd. The Company is headquartered in Ghent,
Belgium. More information can be found onwww.ablynx.com.

For more information, please contact

Ablynx:

Dr Edwin Moses
CEO
t: +32 (0)9 262 00 07
m: +32 (0)473 39 50 68
e: edwin.moses@ablynx.com

Marieke Vermeersch
Associate Director Investor Relations
t: +32 (0)9 262 00 82
m: +32 (0)479 49 06 03
e: marieke.vermeersch@ablynx.com

Follow us on Twitter @AblynxABLX

Ablynx media relations
Instinctif Partners:

Sue Charles, Daniel Gooch
London office
t: +44 (0)20 7866 7905
e: ablynx@instinctif.com

Belgium/Dutch and French language
Jim Rusagara
Brussels office
t: +32 (0)2 626 9500
e: ablynx@instinctif.com

pdf format of the press release
http://hugin.info/137912/R/1993813/734103.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Ablynx via Globenewswire

HUG#1993813

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.